| Literature DB >> 28049395 |
Jerzy Leszek1, Elzbieta Trypka1, Vadim V Tarasov2, Ghulam Md Ashraf3, Gjumrakch Aliev4,5,6.
Abstract
The brain of patients with Alzheimer disease (AD) showed the evidence of reduced expression of insulin and neuronal insulin receptors, as compared with those of age-matched controls. This event gradually and certainly leads to a breakdown of the entire insulin-signaling pathway, which manifests insulin resistance. This in turn affects brain metabolism and cognitive functions, which are the bestdocumented abnormalities in AD. These observations led Dr. de la Monte and her colleagues to suggest that AD is actually a neuroendocrine disorder that resembles type 2 diabetes mellitus. The truth would be more complex with understanding the role of low-density lipoprotein receptor-related protein 1, Aβ derived diffusible ligands, and advanced glycation end products. However, now it known as "brain diabetes" and is called type 3 diabetes mellitus (T3DM). This review provides an overview of "brain diabetes" focusing on the reason why the phenomenon is called T3DM. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.Entities:
Keywords: Alzheimer disease; Diabetes mellitus; Insulin; Type 2 diabetes mellitus; Type 3 diabetes mellitus
Mesh：
Year: 2017 PMID： 28049395 DOI： 10.2174/1568026617666170103163403
Source DB: PubMed Journal: Curr Top Med Chem ISSN： 1568-0266 Impact factor: 3.295